Full TitleA Multi-center Phase II study of CC486-CHOP in Patients with Previously Untreated Peripheral T-cell Lymphoma
CHOP is a combination of four chemotherapy drugs traditionally used to treat peripheral T-cell lymphoma. In this study, researchers are assessing the safety and effectiveness of adding the investigational drug CC-486 (oral azacitidine) to CHOP therapy in patients with peripheral T-cell lymphoma who have not yet been treated.
CC-486 works by changing which genes are active in cancer cells, which can make cancer cells more likely to die in response to chemotherapy. CC-486 and one of the CHOP drugs are taken orally (by mouth); the other three drugs are given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have peripheral T-cell lymphoma that has not yet been treated.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients ages 18-80.
For more information and to inquire about eligibility for this study, please contact Dr. Alison Moskowitz at 212-639-4839.